A post-marketing surveillance survey on the use of dipotassium clorazepate in clinical practice in the Philippines.
A post-marketing surveillance survey of dipotassium clorazepate usage was carried out in the Philippines between July 1990 and April 1991. Data were analyzed on 562 patients suffering from conditions in which anxiety was a major component. The results suggest that the medication was prescribed in accordance with the generally accepted best practice for benzodiazepines. Overall, 85% of patients were reported to have recovered and only 2% reported minor side-effects. Dipotassium clorazepate was thus confirmed to be a highly effective and relatively safe anxiolytic agent.
Perez
G G
GG
Sanofi Winthrop (Asia Pacific Region, Metro Manilla, Philippines.
Tudor
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001008:Anxiety Disorders / Q000188:drug therapy*; D002648:Child; D003009:Clorazepate Dipotassium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008505:Medical Staff, Hospital; D008875:Middle Aged; D010679:Philippines; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011358:Product Surveillance, Postmarketing; D013997:Time Factors; D016896:Treatment Outcome
D003009:Clorazepate Dipotassium